Waleed K. Abdulsahib , Sattar J. Abood

Abstract

To Evaluate the Ocular-hypotensive Effect of Levamlodipine in the Betamethasone- induced Glaucoma Model in the Rabbits. Ocular-hypertension was made by weekly subconjunctival injection of Celestone Chronodose® for four weeks in the right eye and the left eye was left as a control. The animals were divided into three groups, twice-daily eye drops of Levamlodipine 0.25%, Levamlodipine 0.5 %, and Timolol maleate 0.5% were administered to groups 1, 2, and 3 respectively (n = 6 for each group) for 12 days after week 4 of induction. All left eyes (control) administered sterile distilled water (DW) twice daily.

The subconjunctival administration of corticosteroid weekly after four weeks creates a significant (p˂ 0.001) increment in IOP in right eyes in groups 1, 2, and 3. Levamlodipine 0.25% shows a significant decrease in IOP after 3 days (p˂0.001), reaching 23.31±0.56 mmHg. Group 2 that administered 0.5% Levamlodipine, IOP significantly reduced (p˂0.001) (from 23.93±0.61 mmHg to 20.93±0.76 mmHg). Levamlodipine 0.5% produced a significant (p˂ 0.001) drop in the IOP when compared to Levamlodipine 0.25% and Timolol 0.5 in days 6, 9 and 12. During the study period, no systemic adverse events were observed in the left and right eyes of all groups. Levamlodipine has a promising beneficial effect in reducing intraocular pressure in the chronic model of glaucoma‎.

Citation Formats: